The World Dermatological Market Outlook, 2009-2023

Table of Contents

1. Executive Summary

• 1.1 Dermatological Market Review
• 1.2 Aims, Scope and Format of the Report

2. Introduction to Skin Diseases and Treatments

• 2.1 The Structure of the Skin
  • 2.1.1 Hair
  • 2.1.2 Sweat and Sebaceous Glands
  • 2.1.3 Nails
• 2.2 The Physiological Role of the Skin
  • 2.2.1 Protection
  • 2.2.2 Sensory Perception
  • 2.2.3 Storage
  • 2.2.4 Absorption/Vitamin D Formulation
  • 2.2.5 Temperature Regulation
• 2.3 Differences in Skin Due to Gender
• 2.4 The Effects of Age on Skin Structure
• 2.5 Inflammation and Histamine Release
• 2.6 Introduction to Dermatitis
  • 2.6.1 Atopic Dermatitis
  • 2.6.2 Contact Dermatitis
  • 2.6.3 Seborrheic Dermatitis
• 2.7 Introduction to Rosacea
  • 2.7.1 Symptoms
  • 2.7.2 Types and Causation
• 2.8 Introduction to Urticaria
  • 2.8.1 Acute Urticaria
  • 2.8.2 Chronic Urticaria
  • 2.8.3 Physical Urticaria
  • 2.8.4 Dermatographic Urticaria
• 2.9 Introduction to Alopecia
  • 2.9.1 Alopecia Areata
  • 2.9.2 Androgenic Alopecia
  • 2.9.3 Telogen Effluvium
  • 2.9.4 Trichotillomania and Traction Alopecia
• 2.10 Introduction to Skin Infection
  • 2.10.1 Bacterial Skin Infections
  • 2.10.2 Fungal Skin Infections
    • 2.10.2.1 Dermatophyte Infections
  • 2.10.3 Viral Infections
    • 2.10.3.1 Herpes Simplex
    • 2.10.3.2 Chicken Pox
    • 2.10.3.3 Herpes Zpster
    • 2.10.3.4 Warts
• 2.11 Introduction to Acne
  • 2.11.1 Pathogenesis
  • 2.11.2 Causation
  • 2.11.3 The Diagnosis of Acne
• 2.12 Introduction to Psoriasis
  • 2.12.1 Causation
  • 2.12.2 Symptoms
  • 2.12.3 Type
  • 2.12.4 Complications
• 2.13 Common Skin Treatments
  • 2.13.1 Creams and Semisolid Emulsions
  • 2.13.2 Ointments
  • 2.13.3 Lotions
  • 2.13.4 Solutions
  • 2.13.5 Occlusive Therapy
  • 2.13.6 Cleansing Agents
  • 2.13.7 Protectant Powders and Hydrophilic Polymers
  • 2.13.8 Anti-Infective Agents
  • 2.13.9 Anti-Inflammatory Agents

3. An Overview of the World Dermatological Market 2008-2023 (Including Forecasts in the Seven Major Markets)

• 3.1 The World Dermatological Market Analysis
  • 3.1.1 Strategic Analysis
• 3.2 The Leading Dermatological Markets: a Comparison
• 3.3 Medrol Currently Leads the World Dermatological Market - But Will it Last?
• 3.4 The Dermatitis Market Dominates the Dermatological Industry
• 3.5 Pharmaceutical Companies Accept that Dermatological Blockbuster Sales Will Be Difficult to Achieve
• 3.6 While the Past Has Been Difficult for Dermatological Treatments, There is Optimism for the Future
• 3.7 The Top 10 Companies in the Dermatological Market
• 3.8 The Dermatological Market, Regional Breakdown
• 3.9 Dermatological Sales in the Seven Major Markets
  • 3.9.1 Dermatological Market in the US
  • 3.9.2 Dermatological Market in Japan
  • 3.9.3 Dermatological Market in France
  • 3.9.4 Dermatological Market in Germany
  • 3.9.5 Dermatological Market in the UK
  • 3.9.6 Dermatological Market in Italy
  • 3.9.7 Dermatological Market in Spain

4. The World Dermatitis Market Analysis 2008-2023

• 4.1 Dermatitis Market Analysis - Overview
• 4.2 Medrol Currently Leads the Dermatitis and Dermatological Market
  • 4.2.1 Development of Medrol (methylprednisolone acetate)
• 4.3 Celestone Analysis
  • 4.3.1 Development of Celestone (betamethasone)
• 4.4 Elocon Suffers From Generic Competition
  • 4.4.1 Development of Elocon (mometasone fuorate)
• 4.5 Dermovate Will Increase in Revenues During 2008-2013 - But Will Growth Last Beyond that Period
  • 4.5.1 Development of Dermovate/Olux/Clob X (Clobetasol)
• 4.6 Kenacort A to Show an Early Increase in Revenues
  • 4.6.1 Kenacort A
• 4.7 The Dermatitis Market - Summary

5. The World Skin Infection Market Analysis 2008-2023

• 5.1 Skin Infection Market Analysis - Overview
• 5.2 Aldara Currently Leads the Skin Infection Market - But Will it Hold During the Forecast Period
  • 5.2.1 Development of Aldara (imiquimod)
• 5.3 Zovirax Will Show an Early Increase in Revenues
  • 5.3.1 Development of Zovirax (acyclovir)
• 5.4 Bactroban Will Decline in Revenues During the Forecast Period
  • 5.4.1 Development of Bactroban (mupirocin)
• 5.5 Lamisil Will be Affected by Patent Expiration
  • 5.5.1 Development of Lamisil (terbinafine)
• 5.6 Nizoral Will Suffer from Generic Competition
  • 5.6.1 Development of Nizoral (ketoconazole)
• 5.7 The Skin Infection Market - Summary

6 The World Acne Market Analysis 2008-2023

• 6.1 Acne Market Analysis - Overview
• 6.2 Differin Currently Leads the Acne Market
  • 6.2.1 Development of Differin (Adapalene)
• 6.3 Diane Open to Generic Competition
  • 6.3.1 Development of Diane (cyproterone/ethinylestradiol)
• 6.4 Benzaclin Will Exhibit Positive Growth - However Can it Withstand Pressure From its Main Rival?
  • 6.4.1 Benzoyl Peroxide and Clindamycin (Benzaclin and Duac)
• 6.5 Roaccutane Associated With Side Effects
  • 6.5.1 Development of Roaccutane (isotretinoin)
• 6.6 Duac Revenues During the Forecast Period
• 6.7 The Acne Market - Summary

7. The World Psoriasis Market Analysis 2008-2023

• 7.1 Psoriasis Market Analysis - Overview
• 7.2 Raptiva Currently Leads the Psoriasis Market
  • 7.2.1 Development of Raptiva (efalizumab)
• 7.3 Daivobet Growth During the Forecast Period
• 7.4 Dovonex Will Suffer From Strong Competition
• 7.5 Taclonex Sales Trends
  • 7.5.1 Dovonex/Daivobet/Taclonex (calciportiene/betamethasone)
• 7.6 Soriatane Sales Will Be Boosted by its Strong Efficacy in Psoriasis Treatment
  • 7.6.1 Soriatane (acitretin)
• 7.7 The Psoriasis Market - Summary

8. The World Market for Miscellaneous Dermatologicals 2008-2023

• 8.1 Miscellaneous Market Analysis
• 8.2 Proscar Sales Trends from 2008-2023
• 8.3 Will Surgicel Show Positive Sales Growth?
• 8.4 Betadine Shows Some Positive Growth - But Will it Continue?
• 8.5 The Miscellaneous Market - Summary

9. SWOT Analysis of the Dermatological Market

• 9.1 SWOT Analysis
• 9.2 Market Drivers
• 9.3 Market Restraints
• 9.4 There is Scope for Expansion into Related Markets
• 9.5 Advances in Technology Likely to Bring Benefits to the Market
• 9.6 Consumer Bargaining Power
• 9.7 Comparative Studies - a Two Edged Sword
• 9.8 Competition in the Dermatological Market to Become Increasingly Marked
• 9.9 Substitutes and Related Threats
• 9.10 A Discussion of Generic Drugs in This Market - How Great is Their Competitive Threat?

10. Pipeline Developments in the Dermatological Market

• 10.1 The Potential of the Dermatological Market Has Encouraged R&D
• 10.2 New Technology Leads to Interesting Pipeline Developments
• 10.3 Potential Entrants
• 10.4 Late-Stage Pipeline Products in the Dermatitis Sector
• 10.5 Late-Stage Pipeline Products in the Skin Infection Sector
• 10.6 Late-Stage Pipeline Products in the Acne Sector
• 10.7 Late-Stage Pipeline Products in the Psoriasis Sector
• 10.8 Late-Stage Pipeline Products in the Miscellaneous Sector
• 10.9 Innovation Rules for Early-Stage Pipeline Drugs

11. Conclusions

• 11.1 The Dermatological Market is Heading for Gradual Financial Growth
• 11.2 Market Drivers in the Dermatological Sector
• 11.3 Market Restraints in the Dermatological Sector
• 11.4 Medrol Currently Leads the World Dermatological Market
• 11.5 Will the Dermatitis Market Continue to Dominate?
• 11.6 The Skin Infection Market
• 11.7 The Acne Market
• 11.8 The Psoriasis Market
• 11.9 Why Growth in the Overall World Dermatological Market Will Continue

• Table 3.1 The World Dermatological Market Forecast ($m), 2008-2023
• Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Dermatological Markets, 2007 & 2013
• Table 3.3 Top Ten Products in the Dermatological Market ($m), 2007
• Table 3.4 Top 10 Companies Revenues ($m) in the Dermatological Market, 2007
• Table 3.5 Dermatological Market Revenues ($m), Sales by Region 2007
• Table 3.6 Dermatological Market Forecast ($m) in the Seven Major Markets, 2008-2023
• Table 3.7 Dermatological Market Share (%) Comparison in the Seven Major Markets, 2007, 2010 & 2013
• Table 4.1 The World Dermatitis Market ($m) Forecast 2008-2023
• Table 4.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 5.1 The World Skin Infection Market ($m) Forecast 2008-2023
• Table 5.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 6.1 The World Acne Market ($m) Forecast 2008-2023
• Table 6.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 7.1 The World Psoriasis Market ($m) Forecast 2008-2023
• Table 7.2 Top 5 Leading Products Rank Comparison, 2007 and 2023
• Table 8.1 The World Miscellaneous Treatments Market ($m) Forecast, 2008-2023
• Table 9.1 SWOT Chart for the Dermatological Market, 2008-2023
• Table 10.1 Late-Stage Pipeline Drugs for Skin Infection, 2008
• Table 10.2 Late-Stage Pipeline Drugs for Acne, 2008
• Table 10.3 Late-Stage Pipeline Drugs for Psoriasis, 2008
• Table 10.4 Late-Stage Pipeline Drugs for Miscellaneous Disorders, 2008
• Table 11.1 Leading Dermatological Markets Revenue Forecasts ($m), 2008-2023

• Figure 3.1 The Leading Dermatological Markets Revenue ($m), 2008-2023
• Figure 3.2 Leading Dermatological Markets Revenue ($m) Comparison, 2007 & 2013
• Figure 3.3 Leading Dermatological Sectors Market Share (%), 2007
• Figure 3.4 Leading Dermatological Sectors Market Share (%), 2013
• Figure 3.5 Top Ten Products Revenue ($m) in the Dermatological Market, 2007*
• Figure 3.6 Market Share (%) of Top Ten Dermatological Products, 2007
• Figure 3.7 Market Share (%) of the Top 10 Companies, 2007
• Figure 3.8 Market Share (%) of the Dermatological Market by Region, 2007
• Figure 3.9 Dermatological Market Revenue ($m) in the Seven Major Markets, 2007*
• Figure 3.10 Dermatological Market Share (%) in the Seven Major Markets, 2007
• Figure 3.11 Dermatological Market Share (%) in the Seven Major Markets, 2010
• Figure 3.12 Dermatological Market Share (%) in the Seven Major Markets, 2013
• Figure 4.1 Market Share (%) of Leading Dermatitis Products, 2007
• Figure 4.2 Market Share (%) of Leading Dermatitis Products, 2010
• Figure 4.3 Market Share (%) of Leading Dermatitis Products, 2013
• Figure 4.4 Dermatitis Market Revenue Forecast ($m), 2008-2023
• Figure 4.5 Medrol Revenue Forecast ($m), 2008-2023
• Figure 4.6 Celestone Revenue Forecast ($m), 2008-2023
• Figure 4.7 Elocon Revenue Forecast ($m), 2008-2023
• Figure 4.8 Dermovate Revenue Forecast ($m), 2008-2023
• Figure 4.9 Kenacort A Revenue Forecast ($m), 2008-2023
• Figure 5.1 Market Share (%) of the Leading Skin Infection Products, 2007
• Figure 5.2 Market Share (%) of the Leading Skin Infection Products, 2010
• Figure 5.3 Market Share (%) of the Leading Skin Infection Products, 2013
• Figure 5.4 Skin Infection Market Revenue Forecast ($m), 2008-2023
• Figure 5.5 Aldara Revenue Forecast ($m), 2008-2023
• Figure 5.6 Zovirax Revenue Forecast ($m), 2008-2023
• Figure 5.7 Bactroban Revenue Forecast ($m), 2008-2023
• Figure 5.8 Lamisil Revenue Forecast ($m), 2008-2023
• Figure 5.9 Nizoral Revenue Forecast ($m), 2008-2023
• Figure 6.1 Market Share (%) of the Leading Acne Products, 2007
• Figure 6.2 Market Share (%) of the Leading Acne Products, 2010
• Figure 6.3 Market Share (%) of the Leading Acne Products, 2013
• Figure 6.4 Acne Market Revenue Forecast ($m), 2008-2023
• Figure 6.5 Differin Revenue Forecast ($m), 2008-2023
• Figure 6.6 Diane Revenue Forecast ($m), 2008-2023
• Figure 6.7 Benzaclin Revenue Forecast ($m), 2008-2023
• Figure 6.8 Roaccutane Revenue Forecast ($m), 2008-2023
• Figure 6.9 Duac Revenue Forecast ($m), 2008-2023
• Figure 7.1 Market Share (%) of the Leading Psoriasis Products, 2007
• Figure 7.2 Market Share (%) of the Leading Psoriasis Products, 2010
• Figure 7.3 Market Share (%) of the Leading Psoriasis Products, 2013
• Figure 7.4 Psoriasis Market Revenue Forecast ($m), 2008-2023
• Figure 7.5 Raptiva Revenue Forecast ($m), 2008-2023
• Figure 7.6 Daivobet Revenue Forecast ($m), 2008-2023
• Figure 7.7 Dovonex Revenue Forecast ($m), 2008-2023
• Figure 7.8 Taclonex Revenue Forecast ($m), 2008-2023
• Figure 7.9 Soriatane Revenue Forecast ($m), 2008-2023
• Figure 8.1 Market Share (%) of the Leading Miscellaneous Products, 2007
• Figure 8.2 Market Share (%) of the Leading Miscellaneous Products, 2010
• Figure 8.3 Market Share (%) of the Leading Miscellaneous Products, 2013
• Figure 8.4 Miscellaneous Market Revenue Forecast ($m), 2008-2023
• Figure 8.5 Proscar Revenue Forecast ($m), 2008-2023
• Figure 8.6 Surgicel Revenue Forecast ($m), 2008-2023
• Figure 8.7 Betadine Revenue Forecast ($m), 2008-2023

Companies Listed

• Abbott
• Aegis
• Allergan
• Almirall
• Altana
• Astellas
• Bayer
• Bayer Schering
• Berlex
• Biogen Idec
• Boryung
• Cellegy
• Centocor
• Cipher
• Clinuvel
• Dr. Reddy' s Laboratories
• EpiCept
• Galderma
• Genaera
• GlaxoSmithKline
• Gruenenthal
• Isotechnika
• Johnson & Johnson
• LEO Pharma
• L' Oreal
• Lupin
• Manhattan
• Meda
• Medivir
• Merck &Co
• Migenix
• Minnesota 3M
• Moberg Derma
• Mylan
• Nestle (Alcon)
• NexMed
• Novartis
• Nycomed Pharma
• Peplin
• Pfizer
• Procept
• QLT
• Roche
• Sanofi-Aventis
• Schering-Plough
• Shionogi
• Stiefel
• Taro Pharmaceuticals
• Teva
• Tolerx
• Wyeth